eli lilly

CIGNA (NYSE: CI) and Forest Laboratories (NYSE: FRX) reached new 52-week highs of $50.70 and $37.87 per share, respectively, on Thursday but were lower in premarket trading Friday. CIGNA was raised to Outperform as yesterday's Bull of the Day at Zacks. The company has a market cap of $13.6...

Hapoalim is upgrading shares of Eli Lilly & Co. (NYSE: LLY) from Hold to Buy. “We are also increasing our Price Target to $39,” Hapoalim writes. “As a result of better-than-expected 1Q sales, we are increasing our 2011-2014 revenue estimates. Additionally as a result of higher than expected...

Deutsche Bank is out with its report today on Eli Lilly (NYSE: LLY), maintaining Hold. In a note to clients, Deutsche Bank writes, "We view LLY shares as fairly valued - hence our Hold rating. LLY's EPS vulnerability exceeds that of its peers, which have taken actions to improve earnings...

Jefferies is out with its report today on Eli Lilly (NYSE: LLY), maintaining Hold. In a note to clients, Jefferies writes, "Q1 2011 results are better than consensus expectations due to a stronger top-line performance and better than expected operational margins. Non-GAAP 2011 EPS guidance has...

Eli Lilly's (NYSE: LLY) Q1 earnings could be under pressure due to “higher operational costs including the excise fee despite better revenue growth,” Jefferies reports. “We forecast Q1'11E revenues to grow 5.7% (4.2% at CER) to US$5.8bn versus consensus estimate of $5.7bn,” Jefferies writes. “We...

In a report published by Jefferies, Eli Lilly's (NYSE: LLY) Strattera appeal could be an uphill task. Jefferies said that its analysis of the legal issues surrounding the Strattera US patent challenge appeal hearing suggests that the lower court's invalidity ruling is unlikely to be overturned,...

Citi is maintaining its Hold rating on shares of Eli Lilly (NYSE: LLY). “Eli Lilly made an offer to purchase Johnson & Johnson's (NYSE: JNJ) (Janssen) Animal Health Business,” Citi writes. “The Janssen business consists of ~50 products, mostly for swine & poultry, with a geographic presence...

After reviewing Eli Lilly's (NYSE: LLY) 10-K, Citi is providing some comments on the stock. “LLY's net debt position was -$200M leaving 2010 vs. -$2.2B/-$4.5B in ‘09/'08,” Citi writes. “LLY has $6.7B in cash/equivalents. We expect bus. dev. to be the priority for cash rather than debt pay down/...

Jefferies is out with its report on Eli Lilly (NYSE: LLY), updating its estimates on LLY. In a note to clients, Jefferies writes, "Following marginally better-than-expected 2010 financials, lower-than-expected 2011 guidance, and recent negative necitumumab news, we have updated our model. We...

Hapoalim is out with its report today on Eli Lilly (NYSE: LLY), reiterating Hold after reporting in-line 2011 guidance. In a note to clients, Hapoalim writes, "The company forecasted 2011 continuing EPS in the range of $4.15 to $4.30, which contains our previous 2011 EPS estimate of $4.26. At $35....

Jefferies International has published a research report on Eli Lilly (NYSE: LLY) as management believes growth will continue through organic pipeline development and stay strong. In the report, Jefferies writes "We have updated our model following an operationally strong third quarter, despite...

In a report released this morning, J.P. Morgan said that it is attending the Annual Meeting of the American College of Rheumatology (ACR) in Atlanta where encouraging 6-mos Phase 2a data were presented this afternoon for Incyte Corporation (NASDAQ: INCY) and Eli Lilly's (NYSE: LLY) Jak inhibitor,...

Goldman Sachs has issued a research report on Eli Lilly & Company (NYSE: LLY) after the company received a complete response letter for Bydureon, as the FDA has changed its mind on the approval of the drug and has requested more thorough research to be conducted on renally impaired patients...

In a report on core product trends for the week ending 10/1/10, Citigroup reports that Eli Lilly and Company's (NYSE: LLY) Cymbalta posted weekly NRx/TRx of 156,732(-1%)/ 368,914 (-1%);9.9%(-3bp) TRx depression market share. Rolling 4wk/12wk NRx growth rates were +0%/+1%; TRx rates were +1%/+1%.LLY...

Citigroup has issued a research report for Eli Lilly (NYSE: LLY) reporting on trends for the week ending 10/1/2010. In the report, Citigroup writes "We rate Lilly High Risk, largely because of a period of considerable generic risk in 2011-13 that is mitigated in part by a solid drug pipeline....